And 585 patients with untreated ES‐SCLC were randomly assigned to receive either Serplulimab, a PD‐1 inhibitor, in combination with chemotherapy, or a placebo, in a 2:1 ratio. This evidence concerns the gene PDCD1 and small cell lung carcinoma.